Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Trading Arrangement: Trading Arrangement [Axis] Cost of sales Cost of Sales Cost of Sales Maximum Maximum [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Development milestones Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Development Milestone Payments Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Development Milestone Payments Short-Term Debt, Type [Axis] Short-Term Debt, Type [Axis] Title of 12(b) Security Title of 12(b) Security Net loss, diluted Net Income (Loss) Available to Common Stockholders, Diluted Document Fiscal Year Focus Document Fiscal Year Focus Adjustment to Compensation, Amount Adjustment to Compensation Amount Financial Instrument [Axis] Financial Instrument [Axis] Segment Reporting [Abstract] Schedule of Estimated Future Amortization Expense Associated with Intangible Assets Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense [Table Text Block] Schedule of Financial Assets and Liabilities to Fair Value Measurements on Recurring Basis and Level of Input Measurements Fair Value, Assets Measured on Recurring Basis [Table Text Block] Common stock, $0.0001 par value; 200,000,000 shares authorized; 64,754,699 and 51,896,391 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively Common Stock, Value, Issued 2027 Lessee, Operating Lease, Liability, to be Paid, Year One Accrued compensation and related benefits Employee-related Liabilities, Current Restatement Determination Date Restatement Determination Date Cash holdback - working capital Asset Acquisition, Consideration Transferred, Deferred Consideration Asset Acquisition, Consideration Transferred, Deferred Consideration Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Due within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year Royalty payment period term Royalty Payment Period Term Royalty Payment Period Term Equity consideration holdback (in shares) Asset Acquisition, Equity Consideration Transferred, Holdback Shares Asset Acquisition, Equity Consideration Transferred, Holdback Shares Stock-based compensation capitalized to inventory Stock Based Compensation Capitalized to Inventory Stock based compensation capitalized to inventory. Allowance for credit losses Accounts Receivable, Allowance for Credit Loss Accrued expenses and other current liabilities Asset Acquisition, Accrued Expenses And Other Current Liabilities Asset Acquisition, Accrued Expenses And Other Current Liabilities Conversion price Debt Instrument, Convertible, Conversion Price Amendment flag Amendment Flag Total convertible notes payable, net Convertible Notes Payable Current liabilities: Liabilities, Current [Abstract] Provision for doubtful accounts Accounts Receivable, Credit Loss Expense (Reversal) Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Developed technology Developed Technology Rights [Member] Unrealized Loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Net assets acquired Asset Acquisition, Net Assets Acquired Asset Acquisition, Net Assets Acquired Schedule of Remaining Contractual Maturities of Available-for-sale Debt Securities Debt Securities, Available-for-Sale [Table Text Block] Leases [Abstract] Leases [Abstract] Issuance of common stock in connection with asset acquisition Stock Issued During Period, Value, Acquisitions Concentrations of Credit Risk and Off-Balance Sheet Risk Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock-based compensation in connection with asset acquisition (in shares) Share-Based Payment Arrangement, Shares, Asset Acquisition Share-Based Payment Arrangement, Shares, Asset Acquisition Entity Address, State or Province Entity Address, State or Province Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Cumulative translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent PEO Total Compensation Amount PEO Total Compensation Amount Milestones accrued License Agreement, Milestone Amount Payable License agreement milestone amount payable. Inventory reserves and firm commitment losses Inventory Reserves And Firm Purchase Commitment Losses Under Operating Activity Inventory Reserves And Firm Purchase Commitment Losses Under Operating Activity Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Financial assets: Assets, Fair Value Disclosure [Abstract] Asset Acquisition [Axis] Asset Acquisition [Axis] Intangible assets, net Intangible Asset, Excluding Goodwill, after Accumulated Amortization Unvested and outstanding, beginning balance (in shares) Unvested and outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Accounts payable, accrued expenses and other liabilities Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities Accounts payable, accrued expenses and other liabilities. Weighted-average shares of common stock used to compute net loss per share, basic (in shares) Weighted average shares of common stock used to compute net loss per share, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Senior Notes Due At 2029 Senior Notes Due 2029 [Member] Senior Notes Due 2029 Long-term investments Long-Term Investments Reportable Segment Reportable Segment [Member] Reportable Segment Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Other non-current assets Asset Acquisition, Other Non-current Assets Asset Acquisition, Other Non-current Assets Fair Value By Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] 2023 Executive PSUs Performance Stock Units [Member] Performance stock units. Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Total current liabilities Liabilities, Current 2030 Lessee, Operating Lease, Liability, to be Paid, Year Four Short-Term Debt, Type [Domain] Short-Term Debt, Type [Domain] Entity Address, City or Town Entity Address, City or Town Total purchase consideration Total purchase consideration Asset Acquisition, Consideration Transferred Percentage of gross proceeds Percentage Of Gross Proceeds Percentage Of Gross Proceeds Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Class of Stock [Axis] Class of Stock [Axis] Total product sales, net Product sales, net Product [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Net Carrying Amount Intangible Asset, Finite-Lived, after Accumulated Amortization Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net loss, basic Net Income (Loss) Available to Common Stockholders, Basic Number Of Reportable Segments Not Disclosed Flag Number Of Reportable Segments Not Disclosed Flag Number Of Reportable Segments Not Disclosed Flag Accumulated Amortization Intangible Asset, Finite-Lived, Accumulated Amortization Level 2 Fair Value, Inputs, Level 2 [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Induced conversion of convertible debt expense Induced Conversion of Convertible Debt Expense United States UNITED STATES Concentration Risk Type [Axis] Concentration Risk Type [Axis] Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Segment Reporting Segment Reporting [Table Text Block] PIPE Shares PIPE Shares [Member] PIPE Shares Arrangement Type [Axis] Arrangement Type [Axis] Arrangement Type Additional payments to acquire intangible assets Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments Use of Estimates Use of Estimates, Policy [Policy Text Block] Related Party [Axis] Related and Nonrelated Parties [Axis] Achievement of product sales milestones Payments For Achievement Of Product And Sales Milestones Payments For Achievement Of Product And Sales Milestones Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Accrued clinical trials Accrued Clinical Trials Current Accrued clinical trials current. Number of approved medicines Number of Approved Medicines Number of Approved Medicines Proceeds from issuance of convertible notes, net of issuance costs Proceeds from Debt, Net of Issuance Costs Schedule of Undiscounted Future Minimum Payments under Operating Leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Non-cash operating, investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Document Period End Date Document Period End Date Change in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Canceled and forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Net cash used in investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Net assets acquired Asset Acquisition, Assets Acquired And Liabilities Assumed, Net Asset Acquisition, Assets Acquired And Liabilities Assumed, Net Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Principal amount Debt Instrument, Face Amount Holdback liabilities Increase (Decrease) In Holdback liabilities Increase (Decrease) In Holdback liabilities 2028 Lessee, Operating Lease, Liability, to be Paid, Year Two Security Exchange Name Security Exchange Name Effective interest rate (as a percent) Debt Instrument, Interest Rate, Effective Percentage Indemnity holdback Indemnity Holdback [Member] Indemnity Holdback Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Pre-Funded Warrant Pre-Funded Warrant [Member] Pre-Funded Warrant Accrued loss on firm purchase commitments Accrued Loss On Firm Purchase Commitments, Current Accrued Loss On Firm Purchase Commitments, Current Denominator: Earnings Per Share, Basic, Other Disclosure [Abstract] Agency bonds Agency Securities [Member] Restricted cash Restricted Cash Equivalent Lessee Lease Description [Line Items] Lessee, Lease, Description [Line Items] Area of office space Area of Land Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Decrease in ROU assets and lease liabilities due to lease modification Right-of-Use Asset and Lease Liabilities, Decrease due to Lease Modification Right-of-Use Asset and Lease Liabilities, Decrease due to Lease Modification Operating lease liabilities, current Operating Lease, Liability, Current Noncurrent accrued sales deductions Accrued Sales Deduction and Other Noncurrent Liabilities Accrued Sales Deduction and Other Noncurrent Liabilities Accrued interest Interest Payable, Current Investments in continuous unrealized loss position for more than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Name Outstanding Recovery, Individual Name Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Company's term to receive annualized net sales Company's Term To Receive Annualized Net Sales Company's Term To Receive Annualized Net Sales Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] IPR&D Asset Acquisition, In-Process Research and Development Asset Acquisition, In-Process Research and Development Total liabilities Liabilities Trading Symbol Trading Symbol Geographical [Domain] Geographical [Domain] Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Total unrecognized stock-based compensation related to unvested stock option awards granted Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Company Selected Measure Name Company Selected Measure Name Sale of Stock [Domain] Sale of Stock [Domain] Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported Within the Consolidated Balance Sheets Restrictions on Cash and Cash Equivalents [Table Text Block] Amortization of debt discount and offering costs Amortization of debt discount and issuance costs Amortization of Debt Issuance Costs and Discounts Royalty obligations payment period Royalty Payment Obligations Period Royalty payment obligations period. Business Combination, Contingent Consideration, Milestone [Axis] Business Combination, Contingent Consideration, Milestone [Axis] Business Combination, Contingent Consideration, Milestone Asset Class [Domain] Asset Class [Domain] Arrangement Type [Domain] Arrangement Type [Domain] Arrangement Type [Domain] Operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Convertible Notes Debt, Policy [Policy Text Block] Incyte Corporation Incyte Corporation [Member] Incyte Corporation Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Weighted-average shares of common stock used to compute net loss per share, diluted (in shares) Weighted average shares of common stock used to compute net loss per share, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Debt Instrument, Convertible Terms Of Conversion [Domain] Debt Instrument, Convertible Terms Of Conversion [Domain] Debt Instrument, Convertible Terms Of Conversion [Domain] Commercial paper Commercial Paper [Member] U.S. treasury bills US Treasury Securities [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Shire Shire International Gmb H [Member] Shire International GmbH. Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Period for final regulatory stay Loss Contingency, Period Of Final Regulatory Stay Loss Contingency, Period Of Final Regulatory Stay Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Operating lease right-of-use asset Asset Acquisition, Operating Lease Right-Of-Use Assets Asset Acquisition, Operating Lease Right-Of-Use Assets Accrued contract manufacturing and non-clinical costs Accrued Contract Manufacturing And Non Clinical Costs Current Accrued contract manufacturing and non-clinical costs, current. Operating cash flows paid for operating lease Operating Lease, Payments Award Timing Predetermined Award Timing Predetermined [Flag] Stock-based compensation, Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Upfront cash consideration Asset Acquisition, Consideration Transferred, Upfront Cash Consideration Asset Acquisition, Consideration Transferred, Upfront Cash Consideration Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Debt instrument, convertible, conversion ratio Debt Instrument, Convertible, Conversion Ratio Total undiscounted lease payments Lessee, Operating Lease, Liability, to be Paid Accounts payable Asset Acquisition, Accounts Payable Asset Acquisition, Accounts Payable Indemnification equity holdback Indemnification Equity Holdback [Member] Indemnification Equity Holdback Debt instrument remaining life Debt Instruments, Convertible, Remaining Discount Amortization Period Debt Instruments, Convertible, Remaining Discount Amortization Period Unvested and outstanding, beginning balance (in dollars per share) Unvested and outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value All Executive Categories All Executive Categories [Member] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Thereafter Finite Lived Intangible Assets Amortization Expense After Year Four Finite Lived Intangible Assets Amortization Expense After Year Four Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Other comprehensive (loss) income: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Plan Name [Domain] Plan Name [Domain] Asset Acquisition [Domain] Asset Acquisition [Domain] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Number of Awards Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Concentration Risk Type [Domain] Concentration Risk Type [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Segment Reporting Segment Reporting [Text Block] Proceeds from maturities of investments Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Minimum Minimum [Member] Expiration Date Trading Arrangement Expiration Date Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Schedule of Disaggregation of Total Product Sales Disaggregation of Revenue [Table Text Block] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Income Statement Location [Axis] Location, Statement of Income, Balance [Axis] Restricted cash Restricted Cash and Cash Equivalent Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Weighted- Average Remaining Contractual Life (in Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted-Average Remaining Contractual Term Holdback liabilities, current Asset Acquisition, Contingent Consideration, Liability, Current Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Total financial liabilities Beginning balance Ending balance Financial Liabilities Fair Value Disclosure Total fair value of fixed rate convertible notes Convertible Debt, Fair Value Disclosures Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Weighted-Average Remaining Amortization Period (Years) Intangible Asset, Finite-Lived, Useful Life Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Aggregate intrinsic value, vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value New Lease Agreement New Lease Agreement [Member] New Lease Agreement Nature of Operation, Product Information, Concentration of Risk [Table] Nature of Operation, Product Information, Concentration of Risk [Table] Schedule of RSU Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Indemnification equity holdback Indemnification Liability, Fair Value Disclosure Indemnification Liability, Fair Value Disclosure Exercise Price Award Exercise Price Investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Segment Reporting [Line Items] Segment Reporting [Line Items] License agreement milestone amount accrued License Agreement Milestone Amount Accrued License agreement milestone amount accrued. Total unrecognized stock-based compensation Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Total cash, cash equivalents, and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Effect of exchange rate on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Common stock held back in connection with asset acquisition Holdback Shares In Connection With The Asset Acquisition [Member] Holdback Shares In Connection With The Asset Acquisition Convertible Notes Debt Disclosure [Text Block] Debt discount and issuance costs Unamortized debt discount and issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity Component [Domain] Equity Component [Domain] Amended Operating Lease Agreement Amended Operating Lease Agreement [Member] Amended operating lease agreement. PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Asset Acquisitions Asset Acquisitions [Text Block] Asset acquisition. Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Net proceeds from transaction Sale of Stock, Consideration Received on Transaction Adoption Date Trading Arrangement Adoption Date Counterparty Name [Domain] Counterparty Name [Domain] Interest rate (percent) Debt Instrument, Interest Rate, Stated Percentage Total stockholders’ (deficit) equity Beginning balance Ending balance Equity, Attributable to Parent Assets Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Total lease liability Operating Lease, Liability Insider Trading Policies and Procedures [Line Items] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Performance Stock Units Performance Shares [Member] Estimated offering expenses Estimated Offering Expenses Estimated Offering Expenses Equity holdback - indemnity Asset Acquisition, Consideration Transferred, Equity Indemnification Holdback Asset Acquisition, Consideration Transferred, Equity Indemnification Holdback Change in fair value of holdback liabilities Change in fair value Change In Fair Value Of Holdback Liabilities Change In Fair Value Of Holdback Liabilities Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Selling, general and administrative Selling, General and Administrative Expense Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Business Acquisition, Acquiree [Domain] Business Combination [Domain] Canceled and forfeited, weighted-average exercise price (in dollars per share) Canceled and forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Anti-dilutive shares of stock (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of operating segments Number of Operating Segments RSUs Restricted Stock Units (RSUs) [Member] Schedule of Outstanding Potentially Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Entity Central Index Key Entity Central Index Key Additional paid-in capital Additional Paid in Capital, Common Stock Holdback liabilities, noncurrent Asset Acquisition, Contingent Consideration, Liability, Noncurrent All Adjustments to Compensation All Adjustments to Compensation [Member] Business Combination [Axis] Business Combination [Axis] Equity [Abstract] Equity [Abstract] Proceeds from issuance of common stock and pre-funded warrants in private placement, net of issuance costs Proceeds from issuance of private placement Proceeds from Issuance of Private Placement Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net cash (used in) provided by operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Accounts Receivable Accounts Receivable [Member] Income Statement [Abstract] Income Statement [Abstract] Stockholders’ (deficit) equity: Equity, Attributable to Parent [Abstract] Issuance of common stock in connection with equity award plans (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Document Transition Report Document Transition Report Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Realized loss, foreign currency transaction, after tax Realized Gain (Loss), Foreign Currency Transaction, after Tax Operating expenses: Less: Operating Expenses [Abstract] Bluejay Employee Stock Awards Bluejay Employee Stock Awards [Member] Bluejay Employee Stock Awards Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Schedule of Finite Lived Intangible Assets Intangible Asset, Finite-Lived [Table Text Block] Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Total liabilities assumed Asset Acquisition, Liabilities Assumed Asset Acquisition, Liabilities Assumed Assigned License Agreement Assigned License Agreement [Member] Assigned license agreement. Number of Awards Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Weighted-average shares of common stock outstanding, basic (in shares) Weighted Average Number Of Shares Outstanding Excluding Warrant Options, Basic Weighted Average Number Of Shares Outstanding Excluding Warrant Options, Basic City Area Code City Area Code Cash consideration, including cash paid in lieu of equity to satisfy taxes Asset Acquisition, Consideration Transferred, Cash Consideration Asset Acquisition, Consideration Transferred, Cash Consideration Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] Schedule of Product Sales by Geographic Area Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue [Table Text Block] Name Forgone Recovery, Individual Name Unrecognized stock-based compensation related to unvested stock, expected to recognize over weighted-average period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Bile Acid Medicines Bile Acid Medicines [Member] Bile acid medicines. Reserved for future stock awards or option grants Future Stock Awards Or Option Grants [Member] Future stock awards or option grants. Other Other Accrued Liabilities, Noncurrent Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted-Average Grant Date Fair Value per Award Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Statement [Line Items] Statement [Line Items] Total assets Assets Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Common stock reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Common stock issuable upon conversion of convertible notes Common stock issuable upon conversion of convertible notes including make-whole provision Convertible Debt [Member] Payment for contingent milestones Payments For Achievement Of Contingent Milestones Payments For Achievement Of Contingent Milestones Stock-based compensation Employee Benefits and Share-Based Compensation Weighted-average grant-date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Interest expense Interest Expense, Nonoperating Schedule of Stock-based Compensation Reflected in Unaudited Condensed Consolidated Statements of Operations Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Unrealized Gain Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Issuance of common stock in connection with equity award plans Stock Issued During Period, Value, Employee Stock Purchase Plan Sanofi-Aventis Deutschland GmbH Sanofi Aventis Deutschland Gmb H [Member] Sanofi-Aventis Deutschland GmbH. Investments with original maturities at date of purchase to be cash equivalents Investments Classified As Cash And Cash Equivalent Original Maturities Investments classified as cash and cash equivalent original maturities. Other assets Increase (Decrease) in Other Operating Assets Noncurrent accrued loss on firm purchase commitments Accrued Loss On Firm Purchase Commitments, Noncurrent Accrued Loss On Firm Purchase Commitments, Noncurrent Issuance of common stock and pre-funded warrants in private placement, net of issuance costs/ Shares issued in connection with the repurchase of convertible notes maturing in 2029 (in shares) Issuance of common stock and warrants in private placement, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues PEO PEO [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Unrestricted cash, cash equivalents and investments Investments and Cash Stock-based compensation expense Share-Based Payment Arrangement, Expense Other liabilities Total other liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Product Information [Line Items] Product Information [Line Items] Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Policy [Policy Text Block] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Class of warrant or right, exercised (in shares) Class Of Warrant Or Right, Exercised Class Of Warrant Or Right, Exercised Thereafter Lessee, Operating Lease, Liability, to be Paid, After Year Four Lessee operating lease liability payments due after year four. Accumulated Deficit Retained Earnings [Member] Operating lease liabilities, noncurrent Operating Lease, Liability, Noncurrent Total operating expenses Operating Expenses Operating lease liabilities, noncurrent Asset Acquisition, Operating Lease Liabilities, Noncurrent Asset Acquisition, Operating Lease Liabilities, Noncurrent Money market funds Money Market Funds [Member] Cancelled and Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Payments of debt issuance costs Payments of Debt Issuance Costs Corporate debt securities Corporate Debt Securities [Member] Net loss per share, diluted (in dollars per share) Earnings Per Share, Diluted Entity Current Reporting Status Entity Current Reporting Status Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Expected volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Initial recognition Financial Liability Recognized During Period Financial Liability Recognized During Period Total Shareholder Return Amount Total Shareholder Return Amount Variable lease payments Operating Lease, Variable Lease Income Cash holdback - indemnity and working capital Asset Acquisition, Consideration Transferred, Cash Indemnification Holdback And Working Capital Asset Acquisition, Consideration Transferred, Cash Indemnification Holdback And Working Capital Prepaid and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Financial liabilities: Liabilities, Fair Value Disclosure [Abstract] Travere Therapeutics, Inc. Travere Therapeutics, Inc [Member] Travere therapeutics inc. FDA Approval FDA Approval [Member] FDA Approval Accrued deferred debt offering costs Accrued Deferred Debt Offering Costs Accrued Deferred Debt Offering Costs Amortization expense Intangible amortization Intangible Asset, Finite-Lived, Amortization Expense Reconciliation of net loss to net cash (used in) provided by operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Debt conversion inducement expense Debt Conversion Inducement Expense Debt Conversion Inducement Expense Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued Liabilities and Other Liabilities, Current Accrued Liabilities and Other Liabilities, Current Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Milestone payments, payable upon approval Clinical Development And Regulatory Milestone Payments Payable Upon Regulatory Approval Clinical development and regulatory milestone payments payable upon regulatory approval. Financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Product sales, net Revenue from Contract with Customer, Excluding Assessed Tax Property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Milestone payments, payable upon commercialization Clinical Development And Regulatory Milestone Payments Payable Upon Commercialization Clinical development and regulatory milestone payments payable upon commercialization. Schedule of Common Stock Reserved for Issuance Schedule of Stockholders Equity [Table Text Block] Share price (in dollars per share) Shares Issued, Price Per Share Financial Instruments [Domain] Financial Instruments [Domain] Milestone payments, payable Clinical Development And Regulatory Milestone Payments Payable Clinical development and regulatory milestone payments payable. Cash consideration holdback payable upon finalization of working capital adjustments Asset Acquisition, Cash Consideration Holdback Amount Subject To Finalization Of Working Capital Adjustments Asset Acquisition, Cash Consideration Holdback Amount Subject To Finalization Of Working Capital Adjustments Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary of significant accounting policies. Number of awards, vested and exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Intangible Asset, Finite-Lived, Class [Axis] Intangible Asset, Finite-Lived, Class [Axis] License Agreements License Agreements [Text Block] Collaboration and License Agreements Text Block. Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Underlying Securities Award Underlying Securities Amount Issuance of common stock and pre-funded warrants in private placement, net of issuance costs / Shares issued in connection with the repurchase of convertible notes maturing in 2029 Stock Issued During Period, Value, New Issues Acquired in-process research and development Acquired IPR&D Research And Development Expense, Acquired In Process Cost Research And Development Expense, Acquired In Process Cost Proceeds from issuance of common stock pursuant to equity plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Cash and cash equivalents Asset Acquisition, Cash And Cash Equivalents Asset Acquisition, Cash And Cash Equivalents Financial Instruments Financial Instruments Disclosure [Text Block] Weighted-average exercise price, vested and exercisable (in dollars per share) Unvested and outstanding, beginning balance (in dollars per share) Unvested and outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Inventory Increase (Decrease) in Inventories Issuance of common stock in connection with asset acquisition (in shares) Stock Issued During Period, Shares, Acquisitions Debt conversion, converted instrument, shares issued (in shares) Debt Conversion, Converted Instrument, Shares Issued Balance Sheet Components Balance Sheet Components [Text Block] Disclosure of balance sheet components. Weighted-average incremental borrowing rate Operating Lease, Weighted Average Discount Rate, Percent Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Segment Reporting [Table] Segment Reporting [Table] Shares issued in connection with the exchange and repurchase of convertible notes maturing in 2029 Stock Issued Stock option exercise proceeds receivable Stock Option Exercise Proceeds Receivable Stock Option Exercise Proceeds Receivable Stockholders' Equity Temporary Equity And Stockholders Equity Note Disclosure [Text Block] Temporary equity and stockholders equity note disclosure. Increase in operating lease right of use asset Increase (Decrease) In Operating Lease, Right-Of-Use Asset Increase (Decrease) In Operating Lease, Right-Of-Use Asset Sale of Stock [Axis] Sale of Stock [Axis] Schedule of Company’s Operating Leases Lease, Cost [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Other income (expense): Other Nonoperating Income (Expense) [Abstract] All Trading Arrangements All Trading Arrangements [Member] Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Commercialization and Medical Affairs expenses (excluding stock-based compensation) Commercialization and Medical Affairs Expenses (Excluding Stock-Based Compensation) Commercialization and Medical Affairs Expenses (Excluding Stock-Based Compensation) Loss from operations Operating Income (Loss) Asset Acquisitions [Line Items] Asset Acquisitions [Line Items] Asset acquisitions. Current Fiscal Year End Date Current Fiscal Year End Date Novartis Pharma AG Novartis Pharma AG [Member] Novartis Pharma AG Livmarli Livmarli [Member] Livmarli Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Assignment And Licence Agreement, FDA Assignment And Licence Agreement, FDA [Member] Assignment And Licence Agreement, FDA Stock-based compensation in connection with asset acquisition Share-Based Payment Arrangement, Value, Asset Acquisition Share-Based Payment Arrangement, Value, Asset Acquisition Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Commerical Milestones Commerical Milestones [Member] Commerical Milestones Accrued sales deductions and other Accrued Sales Deductions And Other, Current Accrued Sales Deductions And Other, Current Accrued milestone payment Accrued Milestone Payment, Current Accrued Milestone Payment, Current Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Weighted- Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Schedule of Changes in Estimated Fair Value of Holdback Liabilities Schedule Of Changes In Estimated Fair Value Of Holdback Liabilities [Table Text Block] Schedule Of Changes In Estimated Fair Value Of Holdback Liabilities Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common stock, shares issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Finished goods Inventory, Finished Goods, Gross Commercial milestones Commercial Milestones [Member] Commercial Milestones. Schedule of Fair Value and Amortized Cost of Cash Equivalents and Available-for-sale Investments by Major Security Type Schedule Of Cash Equivalents And Available For Sale Securities Reconciliation [Table Text Block] Schedule of cash equivalents and available for sale securities reconciliation. Accrued royalties payable Accrued Royalties, Current Conversion of convertible notes, net into shares of common stock Conversion Of Convertible Notes, Net Conversion Of Convertible Notes, Net Issuance costs Issuance Costs Issuance costs. Cost of sales (excluding intangible amortization) Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Short-term investments Debt Securities, Available-for-Sale, Current Equity Components [Axis] Equity Components [Axis] Accounts receivable Increase (Decrease) in Accounts Receivable Research and development expenses (excluding stock-based compensation) Research and Development Expenses (Excluding Stock-based Compensation) Research and Development Expenses (Excluding Stock-based Compensation) Product and Service [Domain] Product and Service [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Schedule of Consideration Paid and Allocation of Purchase Price for Acquisition Asset Acquisition [Table Text Block] Cash paid for income taxes Income Tax Paid, after Refund Received Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Entity Interactive Data Current Entity Interactive Data Current Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity Small Business Entity Small Business Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent 2029 Lessee, Operating Lease, Liability, to be Paid, Year Three Termination Date Trading Arrangement Termination Date Ownership maximum threshold percentage Ownership Percentage Maximum Threshold Ownership Percentage Maximum Threshold Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Assignment And Licence Agreement, European Medicines Agency Assignment And Licence Agreement, European Medicines Agency [Member] Assignment And Licence Agreement, European Medicines Agency MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Debt Conversion Terms Two Debt Conversion Terms Two [Member] Debt Conversion Terms Two Other assets Other Assets, Noncurrent Senior Subordinated Convertible Note Senior Subordinated Convertible Note [Member] Senior Subordinated Convertible Note Document Type Document Type Fair value of its investments related to credit loss Fair Value of its Investments Related to Credit Loss Fair value of its investments related to credit loss. Fair Value as of Grant Date Award Grant Date Fair Value Total assets acquired Asset Acquisition, Assets Acquired Asset Acquisition, Assets Acquired Exchange and repurchase of 2029 convertible notes Repayments of Convertible Debt Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Arrangement Duration Trading Arrangement Duration Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Proceeds from issuance of long-term debt Proceeds from Issuance of Long-Term Debt Local Phone Number Local Phone Number Work in progress Inventory, Work in Process, Gross Shire Agreement Assignment And License Agreement [Member] Assignment and license agreement. Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Bluejay Acquisition Bluejay Acquisition [Member] Bluejay Acquisition Debt Instrument, Convertible Terms Of Conversion [Axis] Debt Instrument, Convertible Terms Of Conversion [Axis] Debt Instrument, Convertible Terms Of Conversion Redemption principal amount Debt Instrument, Redemption, Principal Amount Outstanding, Threshold Debt Instrument, Redemption, Principal Amount Outstanding, Threshold Other comprehensive (loss) income Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent Schedule of PSU Activity Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block] Net loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Commitments and contingencies Commitments and Contingencies Gross Carrying Value Intangible Asset, Finite-Lived, before Accumulated Amortization Schedule of Other Noncurrent Liabilities Other Noncurrent Liabilities [Table Text Block] Stock options, restricted stock units and performance stock units issued and outstanding Common Stock Options, Restricted Stock Units And Performance Stock Units Issued And Outstanding [Member] Common stock options, restricted stock units and performance stock units issued and outstanding member. Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] 2030 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Four Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Balance Sheet Components [Table] Balance Sheet Components [Table] Balance Sheet Components [Table] Executive Category: Executive Category [Axis] One to two years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One and Two Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One and Two Total Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value Acquisitions, including Intangible Assets and Contingent Consideration Business Combination [Policy Text Block] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Counterparty Name [Axis] Counterparty Name [Axis] Liabilities and Stockholders’ (Deficit) Equity Liabilities and Equity [Abstract] Intangible Asset, Finite-Lived, Class [Domain] Intangible Asset, Finite-Lived, Class [Domain] Acquired in-process research and development Payments to Acquire in Process Research and Development Inventory Total inventory Inventory, Net Award Type [Domain] Award Type [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount 2026 (remaining six months) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Fair Value Measurements Fair Value Disclosures [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Equity consideration Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable U.S. government bonds US Government Agencies Debt Securities [Member] Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Convertible Senior Notes due 2029 Convertible Senior Notes due 2029 [Member] Convertible Senior Notes due 2029 2027 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year One Weighted-average remaining contractual life, vested and exercisable (In Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted-Average Remaining Contractual Term Term of lease Lessee, Operating Lease, Term of Contract PEO Name PEO Name Common stock exceeds Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Geographical [Axis] Geographical [Axis] Contract liability Contract with Customer, Liability Schedule of Short-Term Debt [Table] Short-Term Debt [Table] Regulatory Approval and Commercialization Regulatory Approval and Commercialization [Member] Regulatory Approval and Commercialization Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Interest expense on convertible notes Total interest expense on convertible notes Interest Expense, Debt Convertible notes payable, net, noncurrent Convertible Notes Payable, Noncurrent Long-term investments Debt Securities, Available-for-Sale, Noncurrent Liability Class [Axis] Liability Class [Axis] Lessee Lease Description [Table] Lessee, Lease, Description [Table] Exercised, weighted-average exercise price (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Product Sales, Net Revenue [Policy Text Block] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Accrued professional service fees Accrued Professional Fees, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Payments for acquisition Payments to Acquire Businesses, Gross Fair value of common stock issued in connection with asset acquisition Fair Value Of Common Stock Issued As Payment For Asset Acquisition Fair Value Of Common Stock Issued As Payment For Asset Acquisition Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Senior Notes Due At Two Thousand Twenty Nine Senior Notes Due At Two Thousand Twenty Nine [Member] Senior notes due at two thousand twenty nine. 2028 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Two Cash holdback - indemnity Asset Acquisition, Consideration Transferred, Cash Indemnification Holdback Asset Acquisition, Consideration Transferred, Cash Indemnification Holdback Conversion of convertible notes, net (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Commercial milestones Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Commercial Milestone Payments Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Commercial Milestone Payments Employee stock purchase plan contingently issuable Employee Stock [Member] Ownership threshold percentage Ownership Percentage Threshold Ownership Percentage Threshold Contingent consideration Asset Acquisition, Consideration Transferred, Contingent Consideration Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Leases Lessee, Operating Leases [Text Block] Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Net loss per share, basic (in dollars per share) Earnings Per Share, Basic Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Award Type [Axis] Award Type [Axis] Realized gains or losses on available-for-sale investments Available For Sale Securities Gross Realized Gain Loss Net 1 Available for sale securities gross realized gain loss net 1. Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Unrealized loss on available-for-sale investments Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Accumulated deficit Retained Earnings (Accumulated Deficit) Schedule of Interest Expense Related to Convertible Notes Schedule of Interest on Convertible Debt [Table Text Block] Tabular disclosure of interest expense and the effective interest rate on the convertible debt. Product and Service [Axis] Product and Service [Axis] Trading days Debt Instrument, Convertible, Threshold Trading Days Business Combination, Contingent Consideration, Milestone [Domain] Business Combination, Contingent Consideration, Milestone [Domain] Business Combination, Contingent Consideration, Milestone [Domain] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Add: weighted average of common stock to be issued upon exercise of pre-funded warrants (in shares) Weighted Average Number of Shares, Contingently Issuable Common Stock Common Stock [Member] Financial assets Estimated Fair Value Debt Securities, Available-for-Sale Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Cover [Abstract] Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Rest of the world Non-US [Member] Warrant Shares Warrant Shares [Member] Warrant Shares Coupon interest expense Interest Expense, Debt, Excluding Amortization Contingent milestones Collaborative Arrangement, Rights and Obligations, Contingent Milestone Payments Collaborative Arrangement, Rights and Obligations, Contingent Milestone Payments Concentration of credit risk percentage Concentration Risk, Percentage Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Accounts Receivable Receivable [Policy Text Block] Equity Awards Adjustments Equity Awards Adjustments [Member] Schedule Of Convertible Notes Convertible Debt [Table Text Block] Material unrealized gains or losses recognized Debt Securities, Available-for-Sale, Realized Gain (Loss) Total liabilities and stockholders’ (deficit) equity Liabilities and Equity Prepaid expenses and other current assets Asset Acquisition, Prepaid Expenses And Other Current Assets Asset Acquisition, Prepaid Expenses And Other Current Assets Convertible Senior Notes due 2032 Convertible Senior Notes due 2032 [Member] Convertible Senior Notes due 2032 Options to purchase common stock and restricted stock units Stock Options Share-Based Payment Arrangement, Option [Member] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Equity Award Plan Equity Award Plan [Member] Equity award plan member. Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Asset Class [Axis] Asset Class [Axis] Balance Sheet Components [Line Items] Balance Sheet Components [Line Items] Balance Sheet Components [Line Items] Related Party [Domain] Related and Nonrelated Parties [Domain] Plan Name [Axis] Plan Name [Axis] Tabular List, Table Tabular List [Table Text Block] Assembled workforce Asset Acquisition, Assembled Workforce Asset Acquisition, Assembled Workforce Bluejay Therapeutics, Inc. Bluejay Therapeutics, Inc. [Member] Bluejay Therapeutics, Inc. Payments made for additions to intangible assets Payments for intangible assets Payments to Acquire Intangible Assets Other (expense) income, net Other Nonoperating Income (Expense) Payment for debt exchange and repurchase Payment For Debt Exchange And Repurchase Payment For Debt Exchange And Repurchase Exchange and repurchase of convertible notes maturing in 2029 Decrease in additional paid-in capital Adjustments To Additional Paid In Capital, Exchange And Repurchase Of Convertible Debt Adjustments To Additional Paid In Capital, Exchange And Repurchase Of Convertible Debt 2029 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Three 2026 (remaining six months) Intangible Asset, Finite-Lived, Estimated Amortization Expense, Remainder of Fiscal Year Name Awards Close in Time to MNPI Disclosures, Individual Name Balance Sheet Components [Abstract] Balance Sheet Components [Abstract] Balance sheet components. Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Purchase of investments Payments to Acquire Investments Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Cancelled and Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Sales Agreement Sales Agreement [Member] Sales agreement. Enthorin Therapeutics, LLC and Dart Neuroscience LLC Enthorin Therapeutics, LLC and Dart Neuroscience LLC [Member] Enthorin Therapeutics, LLC and Dart Neuroscience LLC General and administrative expenses (excluding stock-based compensation) General and Administrative Expense Property, Plant and Equipment Property, Plant and Equipment [Member] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Conversion of convertible notes, net Stock Issued During Period, Value, Conversion of Convertible Securities Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Raw materials Inventory, Raw Materials and Supplies, Gross Net operating liabilities, excluding cash acquired, assumed in connection with asset acquisition Asset Acquisition, Liabilities Assumed, Net, Excluding Cash Acquired Asset Acquisition, Liabilities Assumed, Net, Excluding Cash Acquired Preferred stock, $0.0001 par value; 10,000,000 shares authorized, and no shares issued and outstanding as of June 30, 2026 and December 31, 2025 Preferred Stock, Value, Issued Number of customer Number of Customer Number of customer. Adjustment to Compensation: Adjustment to Compensation [Axis] Number of pending claims Loss Contingency, Pending Claims, Number Class of Stock [Domain] Class of Stock [Domain] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activity Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Asset Acquisitions [Table] Asset Acquisitions [Table] Asset acquisitions. Reserved for employee stock purchase plan Employee Stock Purchase Plan [Member] Employee stock purchase plan. Volixibat Volixibat [Member] Volixibat. Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Total financial assets Assets, Fair Value Disclosure Investments Investment, Policy [Policy Text Block] Name Measure Name Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Acquired In-Process Research and Development In Process Research and Development, Policy [Policy Text Block] Other Other Noncash Income (Expense) Debt Conversion Terms One Debt Conversion Terms One [Member] Debt Conversion Terms One Debt Instrument [Line Items] Debt Instrument [Line Items] Percentage notes declared as accrued Debt Instrument, Redemption, Percentage Of Principal Amount Upon Certain Customary Events Of Default Debt Instrument, Redemption, Percentage Of Principal Amount Upon Certain Customary Events Of Default Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Additional Paid-In Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Short-term investments Short-Term Investments Schedule of Computation of Basic and Diluted Net Loss Per Share Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block] Name Trading Arrangement, Individual Name Fair value of debt conversion, converted instrument Debt Conversion, Converted Instrument, Fair Value Debt Conversion, Converted Instrument, Fair Value Cash and cash equivalents Cash and Cash Equivalent Cash consideration holdback Asset Acquisition, Cash Consideration Transferred, Holdback Amount Asset Acquisition, Cash Consideration Transferred, Holdback Amount Rent expense Operating Lease, Expense Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Company Selected Measure Amount Company Selected Measure Amount Asset Purchase Agreement Asset Purchase Agreement [Member] Asset purchase agreement. Depreciation and amortization Depreciation, Depletion and Amortization Product sales milestone payments, payable Milestone Payment Payable Upon Achievement Of Product Sales Milestone payment payable upon achievement of product sales. Entity Address, Address Line Two Entity Address, Address Line Two Assembled workforce Assembled Workforce [Member] Assembled workforce. Schedule Of Stock By Class [Table] Stock, Class of Stock [Table] Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Current assets: Assets, Current [Abstract] Weighted-average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary of significant accounting policies. Non-PEO NEO Non-PEO NEO [Member] Number of product candidates Number Of Product Candidates Number of product candidates. Date of incorporation Entity Incorporation, Date of Incorporation Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Entity Address, Address Line One Entity Address, Address Line One Right-of-use assets obtained in exchange for lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Provision for income taxes Income Tax Expense (Benefit) Payments and accruals for achievement of various clinical development, regulatory and commercial milestones Payments and Accruals For Achievement Of Various Clinical Development, Regulatory And Commercial Milestones Payments For Achievement Of Various Clinical Development, Regulatory And Commercial Milestones Customer Concentration Risk Customer Concentration Risk [Member] Award Timing Method Award Timing Method [Text Block] Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development Research and Development Expense (Excluding Acquired in Process Cost) Expected volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Statement [Table] Statement [Table] Non-cash lease expense Non Cash Lease Expense Noncash lease expense. Restatement Determination Date: Restatement Determination Date [Axis] Number of warrants issued (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Senior Notes Due At 2032 Senior Notes Due 2032 [Member] Senior Notes Due 2032 Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Interest income Investment Income, Interest Reduction in additional paid-in capital related to the exchange and repurchase of notes maturing in 2029 Reduction in additional paid-in capital related to the exchange and repurchase of notes Debt Conversion, Converted Instrument, Amount Consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Number of claims filed Loss Contingency, New Claims Filed, Number Takeda Takeda [Member] Takeda Transaction costs Asset Acquisition, Consideration Transferred, Transaction Cost Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Development or regulatory milestones incurred Development or Regulatory Milestones Incurred Development or regulatory milestones incurred Share-Based Payment Arrangement Share-Based Payment Arrangement [Member] Total cash equivalents and investments Cash Equivalents And Available For Sale Securities Debt Securities Cash equivalents and available for sale securities debt securities. Unrealized foreign exchange loss (gain) Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Upfront equity consideration (in shares) Asset Acquisition, Consideration Transferred, Upfront Equity Consideration, Shares Asset Acquisition, Consideration Transferred, Shares Of Upfront Equity Consideration, Revenue: Revenues [Abstract] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Numerator: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]